Lutein: History and Discovery

Lutein has been hiding in plain sight for as long as people have looked at the world: it is the yellow in an egg yolk, in a marigold petal, in autumn leaves, and in the small yellow spot at the center of the human eye. But understanding what that yellow was — naming the molecule, working out its chemical structure, and finally proving that it is one of the pigments that protects our central vision — took more than a century of careful chemistry. This article follows that documented trail: the nineteenth-century chemists who first crystallized and named “lutein,” the Nobel-laureate “golden age” of carotenoid chemistry that settled its structure, the long puzzle of the eye's mysterious “yellow spot,” the moment in the 1980s when two researchers finally identified that pigment as lutein and zeaxanthin, and the landmark eye-health trial that made lutein a household supplement. Where the record is firm we say so; where a name or date is uncertain or contested, we flag it.

Table of Contents

  1. A Name That Means “Yellow”
  2. The Golden Age of Carotenoid Chemistry
  3. The Eye's Mysterious “Yellow Spot”
  4. 1985: Naming the Macular Pigment
  5. A Third Pigment Made Inside the Eye
  6. Why the Eye Hoards Lutein: The Binding Proteins
  7. From Laboratory to AREDS2
  8. Marigolds, Eggs, and the Diet Story
  9. Research Papers and References
  10. Connections
  11. Featured Videos

A Name That Means “Yellow”

The story of lutein begins not with a discovery but with a word. The name comes straight from the Latin luteus, meaning “yellow,” and that is the whole point: lutein is, before anything else, a yellow pigment. It colors marigold petals, egg yolks, corn, and the flesh of yellow fruits, and it is one of the pigments revealed in leaves each autumn as the green chlorophyll fades.

The term itself is a nineteenth-century coinage. The English-language record — including the Oxford English Dictionary, whose earliest cited use of “lutein” dates to 1869 — traces the word to the German-British physician and pioneering biochemist Johann Ludwig Wilhelm Thudichum (1829–1901), who applied the name (in the form luteine) around 1868–1869 to yellow, crystallizable coloring matter he was studying. Thudichum is better remembered today as a founder of brain chemistry, but he worked across many biological pigments, and the name he gave the yellow ones has stuck ever since. It is worth being precise here: Thudichum named a class of yellow substances; he did not isolate the single, pure molecule we now call lutein, and the “lutein” of early literature was a looser category than the defined compound of modern chemistry.

That looseness matters, because the same root word produced a second, unrelated meaning in anatomy. The corpus luteum — the “yellow body” that forms in the ovary — and hormones such as “luteinizing hormone” take their names from the same Latin luteus, simply because that tissue, too, looks yellow. The shared root is a coincidence of color, not of chemistry; the carotenoid lutein and the reproductive corpus luteum are different things that happen to be named for the same hue. Readers sometimes encounter both meanings and assume a connection; there is none beyond the color yellow.

Back to Table of Contents

The Golden Age of Carotenoid Chemistry

Through the late nineteenth and early twentieth centuries, chemists slowly sorted the plant pigments into families. The bright yellow-to-red fat-soluble pigments became known collectively as carotenoids — named after the carrot, from which an orange pigment had been crystallized as early as 1831. Within that group a key distinction emerged between two sub-families: the carotenes, which are pure hydrocarbons (carbon and hydrogen only), and the xanthophylls (from the Greek for “yellow leaf”), which also contain oxygen. Lutein, with two oxygen-bearing hydroxyl groups, belongs to the xanthophylls.

The decisive chemistry came from a remarkable cluster of researchers later described as the field's “golden age.” The German chemist Richard Willstätter — awarded the Nobel Prize in Chemistry in 1915, chiefly for his work on chlorophyll — helped establish the molecular formulas that separated the simple carotenes (a C₄₀H₅₆ backbone) from the oxygen-containing xanthophylls (C₄₀H₅₆O₂), the formula lutein shares. Building on this, the Swiss chemist Paul Karrer elucidated the structures of beta-carotene and then of the major xanthophylls; his work on carotenoids and vitamins earned him the Nobel Prize in Chemistry in 1937. The German chemist Richard Kuhn, who received the Nobel Prize in Chemistry in 1938, worked in parallel on the carotenoids and their stereochemistry. Standard histories of the field credit the structural elucidation of lutein, zeaxanthin, and related xanthophylls to this Karrer–Kuhn era of the 1930s.

By the eve of the Second World War, then, chemists knew what lutein was as a molecule — a 40-carbon xanthophyll with a hydroxyl group on each end ring — even though no one yet knew what it did inside the human body. That second question would take another half-century, and it would be answered not by chemists at the bench but by scientists peering into the retina.

Back to Table of Contents

The Eye's Mysterious “Yellow Spot”

Anatomists had noticed something odd about the human retina for a very long time. At the center of the retina, in the region responsible for our sharpest vision, sits a faintly yellow patch. Early anatomical descriptions of this “yellow spot” in the human eye reach back to the close of the eighteenth century, and the structure was given the Latin name that still describes it: macula lutea — literally “yellow spot.” For more than a century, though, the identity of that yellow was simply unknown. Anatomists could see the color; nobody could say which molecule produced it.

The first major step came in 1945, when the American scientist George Wald — who would later share the 1967 Nobel Prize in Physiology or Medicine for his work on the chemistry of vision — reported that the absorption spectrum of the macular pigment matched that of a xanthophyll carotenoid. In his paper “Human Vision and the Spectrum,” published in Science, Wald reasoned that because animals cannot make carotenoids, this pigment in the eye must ultimately come from the diet. Wald established the family of the pigment and recognized its dietary origin, but the tools of his day could not separate and name the exact molecules involved. The yellow of the macula was now known to be a xanthophyll — but precisely which xanthophylls remained an open question for another forty years.

Back to Table of Contents

1985: Naming the Macular Pigment

The question Wald left open was finally answered in the mid-1980s, and the credit belongs to a partnership of two researchers in Florida: the physicist Richard A. Bone and the chemist John T. Landrum. Using high-performance liquid chromatography (HPLC) — a separation technique far more powerful than anything available to Wald — they extracted the pigment from human retinas and compared it against pure chemical standards.

In 1985, Bone, Landrum, and their colleague S. L. Tarsis published “Preliminary identification of the human macular pigment” in Vision Research, reporting that the macular pigment separated into components matching lutein and zeaxanthin. A follow-up analysis in 1988 confirmed it: the yellow of the macula was made of these two dietary xanthophylls and no others. After nearly two centuries, the “yellow spot” finally had a chemical name.

This is the genuine discovery moment in lutein's story for human health. Like all dietary nutrients, lutein has no single human “inventor” — plants made it long before we studied it. What Bone and Landrum did was specific and datable: they identified the molecules responsible for the macular pigment, turning a vague anatomical curiosity into a defined nutritional target. Nearly every later study of lutein and eye health — including the large clinical trials — rests on that 1985 identification.

Back to Table of Contents

A Third Pigment Made Inside the Eye

The story had one more twist. As analytical methods sharpened, Bone and Landrum found that the macula does not contain just two pigments but three. In a 1993 study of the stereochemistry of the macular carotenoids, published in Investigative Ophthalmology & Visual Science, they showed that part of what had been measured as “zeaxanthin” was actually a distinct stereoisomer — meso-zeaxanthin — that is essentially absent from the ordinary diet.

The natural conclusion, supported by their data, was striking: if meso-zeaxanthin is not something we eat, the eye must be making it on the spot, most likely by converting dietary lutein inside the retina itself. In other words, lutein is not only deposited in the macula; it appears to serve as the raw material the eye uses to manufacture a second protective pigment. That finding underlined just how central lutein is to the chemistry of central vision — it is both a building block and a finished product of the macular pigment. (Some specifics of meso-zeaxanthin's exact origin and the enzymes involved are still researched; what the historical record firmly supports is that the third macular carotenoid is largely non-dietary and derived within the eye.)

Back to Table of Contents

Why the Eye Hoards Lutein: The Binding Proteins

Identifying the pigments raised an obvious follow-up question. Dozens of carotenoids circulate in human blood, yet the macula admits only lutein, zeaxanthin, and meso-zeaxanthin and rejects all the rest. How does the eye choose so selectively? The answer, worked out in the 2000s, is that the retina has dedicated carotenoid-binding proteins — molecular escorts that grab specific xanthophylls and hold them in place.

In 2004, a team led by Prakash Bhosale and Paul S. Bernstein identified a particular form of an enzyme — the pi isoform of glutathione S-transferase, GSTP1 — as the protein that selectively binds zeaxanthin (and meso-zeaxanthin) in the human macula. Their work appeared in the Journal of Biological Chemistry. Then, in 2011, a study led by Binxing Li and Bernstein, published in the journal Biochemistry, identified StARD3 (also known as MLN64) as the corresponding lutein-binding protein in the primate macula.

Together these discoveries explained the selectivity Wald had only hinted at and Bone and Landrum had measured: the eye does not passively soak up whatever carotenoid drifts by. It has evolved specific proteins to capture lutein and zeaxanthin from the bloodstream and concentrate them exactly where focused light, high oxygen use, and fragile membranes make protection most urgent. The dietary nutrient and the dedicated transport machinery are two halves of the same evolved system.

Back to Table of Contents

From Laboratory to AREDS2

Knowing that lutein and zeaxanthin build the macular pigment, and that the body cannot make them, pointed to an obvious clinical question: could increasing intake help protect against age-related macular degeneration (AMD), the leading cause of irreversible central vision loss in older adults? The original Age-Related Eye Disease Study (AREDS), reported in 2001, had shown that a high-dose antioxidant-and-zinc formula slowed progression to advanced AMD — but that formula relied on beta-carotene, which separate trials had linked to increased lung-cancer risk in smokers.

The follow-up trial, AREDS2, was designed largely to test whether lutein and zeaxanthin could safely take beta-carotene's place. Conducted by the AREDS2 Research Group and published in JAMA in 2013 (Chew and colleagues), it randomized more than 4,000 people at high risk of advanced AMD. The trial found that adding lutein (10 mg) plus zeaxanthin (2 mg) protected against progression to advanced AMD about as well as beta-carotene — but without the lung-cancer signal — and that swapping the xanthophylls in for beta-carotene further reduced progression, with the greatest benefit in people who had eaten the least lutein and zeaxanthin to begin with.

The practical outcome was that the standard eye-health formula was rewritten: the modern AREDS2 formulation replaces beta-carotene with lutein and zeaxanthin. For a molecule first crystallized and named in the 1800s, this was the moment it entered tens of millions of medicine cabinets. (As always with history, the honest caveat belongs here too: AREDS2 showed slowed progression in people already at high risk — not that the formula prevents AMD in healthy, low-risk eyes. The detailed evidence, dosing, and cautions live on the main Lutein page.)

Back to Table of Contents

Marigolds, Eggs, and the Diet Story

Running underneath the laboratory history is a much older, quieter one: lutein has always been part of what people eat. Long before it had a name, it colored the staple foods of the human diet — the deep yellow of an egg yolk, the gold of sweet corn, the hidden pigment in every leafy green where it sits masked behind chlorophyll. Traditional poultry-keepers knew, in practical terms, that birds fed marigold petals, corn, or green forage laid eggs with richer yellow yolks and grew yellower skin and fat; that folk knowledge was simply lutein and its xanthophyll relatives moving up the food chain, though no one called it that.

That same observation became an industry. The petals of the marigold (Tagetes erecta) are exceptionally rich in lutein, and marigold extract became the standard commercial source — first as a feed additive to color egg yolks and poultry, and later, once the eye research matured, as the raw material for human lutein supplements. Modern food regulators recognize marigold-derived lutein as a coloring agent (it carries the European food-additive code E161b), a direct administrative descendant of the centuries-old practice of feeding marigolds to chickens for golden yolks.

Nutrition research eventually closed the loop between the food and the eye. Controlled feeding studies in the 1990s and after showed that the lutein in egg yolk is unusually well absorbed — because it arrives already dissolved in the yolk's fat — and that adding eggs or leafy greens to the diet measurably raises blood lutein and, over time, the pigment in the macula itself. The thread that runs through the whole history is a single, unbroken one: the yellow that traditional farmers prized in their eggs is the same molecule that nineteenth-century chemists named, that Karrer and Kuhn drew the structure of, and that Bone and Landrum finally found guarding the center of human sight.

Back to Table of Contents

Research Papers and References

The list below gathers the key peer-reviewed milestones in lutein's scientific history, followed by curated PubMed topic searches and authoritative resources. Author names, titles, and journals are given as plain text; only a stable DOI or PubMed (PMID) link is hyperlinked, and each opens in a new tab. The etymology of “lutein” (Thudichum, 1868–1869) and the early naming of carotenoids are described in the article as historical points of record rather than as modern citations.

  1. Wald G. Human vision and the spectrum. Science. 1945;101(2635):653–658. — doi:10.1126/science.101.2635.653
  2. Bone RA, Landrum JT, Tarsis SL. Preliminary identification of the human macular pigment. Vision Research. 1985;25(11):1531–1535. — PMID: 3832576
  3. Bone RA, Landrum JT, Hime GW, Cains A, Zamor J. Stereochemistry of the human macular carotenoids. Investigative Ophthalmology & Visual Science. 1993;34(6):2033–2040. — PMID: 8491553
  4. Bhosale P, Larson AJ, Frederick JM, Southwick K, Thulin CD, Bernstein PS. Identification and characterization of a Pi isoform of glutathione S-transferase (GSTP1) as a zeaxanthin-binding protein in the macula of the human eye. Journal of Biological Chemistry. 2004;279(47):49447–49454. — PMID: 15355982
  5. Li B, Vachali P, Frederick JM, Bernstein PS. Identification of StARD3 as a lutein-binding protein in the macula of the primate retina. Biochemistry. 2011;50(13):2541–2549. — PMID: 21322544
  6. Age-Related Eye Disease Study 2 (AREDS2) Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the AREDS2 randomized clinical trial. JAMA. 2013;309(19):2005–2015. — doi:10.1001/jama.2013.4997
  7. Landrum JT, Bone RA. Lutein, zeaxanthin, and the macular pigment. Archives of Biochemistry and Biophysics. 2001;385(1):28–40. — doi:10.1006/abbi.2000.2171
  8. Lutein history and discovery — PubMed: lutein macular pigment history and discovery
  9. Macular pigment identification (lutein and zeaxanthin) — PubMed: macular pigment lutein and zeaxanthin identification

External Authoritative Resources

Back to Table of Contents

Connections

Back to Table of Contents